CLINICAL EVALUATION OF T-AYU-HMTM IN THE MANAGEMENT OF SICKLE CELL ANEMIAAbstract
Sickle cell anemia is a hemoglobin disorder, which is an autosomal recessive type affects millions of children of underprivileged and tribal area every year. Because of its devastating complications sickle cell is considered a major health problem in India and the entire world. Since many years, majority of the tribal population in the South Gujarat region are suffering from this lifelong disorder, which is incurable till date. The study to clinically evaluate T-AYU-HMTM, a novel herbo-mineral preparation has been performed in patients with sickle cell anemia. The prior ethics approval for the study was obtained. This study was a non-randomized and efficacy comparative type study in which folic acid used as standard. The results were analyzed by using mean ± SEM and one-way analysis of variance. Results from the study show the drug is effective in alleviating the clinical symptoms of patients. Results showed drug is able to sustain the level of red blood corpuscle. The drug also sustained hemoglobin level by reducing sickle hemoglobin balancing it with raising fetal hemoglobin. This sustained level might be responsible for alleviating the symptoms and better observational health-related outcome in sickle cell anemia patients as compared to folic acid treatment. The drug shows superior results on the clinical symptoms of sickle cell anemia patients as compared to folic acid treatment. As one has to tolerate the medicine for a lifetime in sickle cell anemia, T-AYU-HMTM might become the ultimate option in its management in future.
A. M. Desai *, M. N. Saraf, C. Desai, H. Desai and M. Dalal
Dhanvantari Clinic, Ayurveda Health Care and Research Center, Vyara, Gujarat, India.
18 June, 2018
09 July, 2018
28 July, 2018
01 August, 2018